At the end of February, Andrew Aswani, MD, PhD (Santersus AG Chief Medical Officer) participated in the 10th Annual UC San Diego Essentials & Advances in Apheresis Therapies. Dr. Aswani had the opportunity to share current success regarding Santersus and our development of the selective therapeutic cell-free DNA/NET apheresis device to a large audience of physicians and allied health professionals from all around the world, including both established practitioners and those embarking on a new apheresis service.